Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income from Continuing Operations (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Income from Continuing Operations for 15 consecutive years, with 10584000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 1691.58% to 10584000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24559000.0 through Dec 2025, down 528.27% year-over-year, with the annual reading at 14182000.0 for FY2025, 13.27% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 10584000.0 at Aytu Biopharma, down from 1965000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 3940000.0 in Q1 2025, with the low at 53291000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 9481789.47, with a median of 6693000.0 recorded in 2022.
  • Peak annual rise in Income from Continuing Operations hit 272.2% in 2025, while the deepest fall reached 1691.58% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 11548000.0 in 2021, then surged by 42.04% to 6693000.0 in 2022, then skyrocketed by 108.95% to 599000.0 in 2023, then increased by 11.02% to 665000.0 in 2024, then tumbled by 1691.58% to 10584000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 10584000.0, 1965000.0, and 19880000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.